Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2011

01-07-2011 | Original paper

Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case–control study

Authors: Mona Jeffreys, Kate Northstone, Jeffrey Holly, Pauline Emmett, David Gunnell

Published in: Cancer Causes & Control | Issue 7/2011

Login to get access

Abstract

Previous studies have suggested that pregnancy measures of insulin-like growth factors (IGFs) may be related to breast cancer risk in mothers. IGFs may also be important in cervical cancer etiology. We conducted a nested case–control study (69 breast cancer cases, 151 cervical cancer cases, 443 controls) among mothers of the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. Over 70% of blood samples was taken prior to 15 weeks’ gestation; the remainder before 30 weeks. Logistic regression, controlling for maternal age, gestational age, and sample type (plasma/serum) was used to model the association between IGFs and maternal cancer risk. Neither IGF-I nor IGF-II were associated with breast or cervical cancer. IGF-binding protein (BP)-3 was not related to breast cancer, but there was a suggestion that women in the highest compared to lowest quartile of IGFBP-3 had reduced risk of cervical cancer, OR 0.43 (95% CI 0.21–0.86). In conclusion, the importance of IGFs measured in pregnancy and later breast and cervical cancer remains unclear, though IGFBP-3 may be a marker of lowered risk.
Literature
1.
Rowlands M-A, Gunnell D, Harris R, Vatten L, Holly J, Martin R (2009) Circulating insulin-like growth factor (IGF) peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429PubMedCrossRef
2.
Chen B, Liu S, Xu W, Wang X, Zhao W, Wu J (2009) IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies. J Exp Clin Cancer Res. doi:10.​1186/​1756-9966-28-89
3.
Renehan A, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 13:273–278PubMedCrossRef
4.
The Endogenous Hormones Breast Cancer Collaborative Group (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11:530–542CrossRef
5.
de Assis S, Hilakivi-Clarke L (2006) Timing of dietary estrogenic exposures and breast cancer risk. Ann N Y Acad Sci 1089:14–35PubMedCrossRef
6.
Chen T, Lukanova A, Grankvist K et al (2010) IGF-I during primiparous pregnancy and maternal risk of breast cancer. Breast Cancer Res Treat 121:169–175PubMedCrossRef
7.
Lukanova A, Toniolo P, Zeleniuch-Jacquotte A et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(12):2489–2493PubMedCrossRef
8.
Druckmann R, Rohr U (2002) IGF-1 in gynaecology, obstetrics: update. Maturitas 41(Suppl 1):S65–S83PubMedCrossRef
9.
Harris T, Burk R, Yu H et al (2009) Insulin-like growth factor axis and oncogenic human papillomavirus natural history. Cancer Epidemiol Biomarkers Prev 17(1):245–248CrossRef
10.
Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M (2003) Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 9(9):3356–3361PubMed
11.
Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT (2003) Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol 91(3):486–493PubMedCrossRef
12.
Golding J, Pembrey M, Jones R (2001) ALSPAC—The Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol 15(1):74–87PubMedCrossRef
13.
Chellakooty M, Vangsgaard K, Larsen T et al (2004) A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. J Clin Endocrinol Metab 89(1):384–391PubMedCrossRef
14.
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928PubMedCrossRef
15.
Huang YF, Shen MR, Hsu KF, Cheng YM, Chou CY (2008) Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br J Cancer 99(7):1096–1102PubMedCrossRef
16.
Serrano ML, Sanchez-Gomez M, Bravo MM (2007) Insulin-like growth factor system gene expression in cervical scrapes from women with squamous intraepithelial lesions and cervical cancer. Growth Horm IGF Res 17(6):492–499PubMedCrossRef
17.
Schaffer A, Koushik A, Trottier H et al (2007) Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 16(4):716–722PubMedCrossRef
18.
Wu MH, Chou YC, Chou WY et al (2010) Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: evidence from a case-control study. Int J Cancer 126(2):508–514PubMedCrossRef
19.
Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG (1983) ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 303(5920):767–770PubMedCrossRef
20.
Lee AV, Cui X, Oesterreich S (2001) Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7(12 Suppl):4429s–4435sPubMed
21.
Bernard L, Legay C, Adriaenssens E, Mougel A, Ricort JM (2006) Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 350(4):916–921PubMedCrossRef
Metadata
Title
Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case–control study
Authors
Mona Jeffreys
Kate Northstone
Jeffrey Holly
Pauline Emmett
David Gunnell
Publication date
01-07-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 7/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9767-y

Other articles of this Issue 7/2011

Cancer Causes & Control 7/2011 Go to the issue

Brief report

Hat, shade, long sleeves, or sunscreen? Rethinking US sun protection messages based on their relative effectiveness

Original paper

Green tea and coffee consumption and its association with thyroid cancer risk: a population-based cohort study in Japan

Original paper

Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort

Original paper

Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study

Original paper

Variation in the CYP19A1 gene and risk of colon and rectal cancer

Original paper

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits